| 2004N-0330 - Joint Meeting of the Psychopharmacologic Drugs Advisory Committee and the Pediatric Advisory Committee|
|FDA Comment Number :||EC6|
|Submitter :||Dr. Ruby Martinez||Date & Time:||08/30/2004 02:08:12|
|Organization :||National Latino Behavioral Health Association|
|Health Care Association|
| While we recognize the risks associated with the use of psychotropic medication with children, we must also recognize the potentially greater risk of failing to treat debilitating symptoms in this patient group. The National Latino Behavioral Health Association supports the careful and judicious use of medication in appropriately selected children when other less invasive measures (e.g. therapy) have been attempted and have failed to control symptoms that disable or endanger the well- being of the child. In these instances, after informed consent is obtained, the prescriber should pro-ceed cautiously, using low doses and lower-risk medications first. Close follow up will be essen-tial, monitoring the child's response and involving the family as treatment and legal considerations dictate. The use of psychotropic medications in children is controversial and needs to be researched, the current data base in this area is inadequate. The building of the sci-ence in this area will improve the safety and efficacy of treatment in the future.
Ruby J. Martinez, RN, PhD, APRN-BC
President Elect, NLBHA